Le Lézard
Classified in: Ebola virus, Health, Business
Subjects: ERN, CCA

Aethlon Medical Announces Third Quarter Financial Results and Provides Corporate Update


SAN DIEGO, Feb. 11, 2019 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health, today reported financial results for the third quarter ended December 31, 2018 and provided an update on recent developments.

Company Updates

Timothy C. Rodell, M.D., FCCP, joined the Company as Interim Chief Executive Officer and as a member of the Board of Directors in December 2018.  Along with the recent additions to the Board of Directors of Sabrina Martucci-Johnson and Guy Cipriani, and the appointment of Charles Fisher, M.D. as Chairman, the Company believes it has the team in place with the depth of experience to move through the next stages of development.

The Company is continuing the development of its proprietary Hemopurifier, which is a first in class therapeutic device designed for the single use depletion of circulating viruses and cancer-promoting exosomes.  The Hemopurifier had previously been designed as a Breakthrough Device by the FDA for the treatment of glycosylated viruses, including Ebola and other hemorrhagic fever viruses, and, as previously announced, during this quarter was additionally designated as a Breakthrough Device ".....for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease....". 

While the Company continues to identify potential development pathways in viral diseases, the primary focus remains advancing the Hemopurifier for oncology indications under the Breakthrough Device designation as rapidly as possible.

In support of this development program, the Company is continuing work under an ongoing Small Business Innovation Research (SBIR) grant from the National Cancer Institute entitled "The Hemopurifier Device for Targeted Removal of Breast Cancer Exosomes from Blood Circulation".

Third Quarter Financial Results

The Company's net loss was approximately $2.0 million, or $(0.11) per share, for the three months ended December 31, 2018, compared to a net loss of approximately $1.2 million, or $(0.08) for the three months ended December 31, 2017.

At December 31, 2018, the Company had a cash balance of approximately $4.8 million.

Consolidated operating expenses for the three months ended December 31, 2018 were approximately $1.96 million, compared to $1.24 million for the three months ended December 31, 2017.  This increase of approximately $720,000, or 58.6%, was due to increases in payroll and related expenses of approximately $498,000, professional fees of approximately $148,000, and general and administrative expenses of approximately $79,000.

The $498,000 increase in payroll and related expenses was primarily due to the combination of a $473,000 accrual for separation payments over calendar 2019 for the Company's former CEO and President and a $22,000 increase in stock-based compensation.

The $148,000 increase in our professional fees was primarily due to increased scientific consulting fees related to ongoing studies.

The $79,000 increase in general and administrative expenses was primarily due to a $45,000 accrual for health insurance payments over calendar 2019 for the Company's former CEO and President.

The Company had other expense of approximately $55,000 in the three months ended December 31, 2018, compared to other expense of approximately $56,000 in the three months ended December 31, 2017.

The unaudited condensed consolidated balance sheet for December 31, 2018 and the unaudited condensed consolidated statements of operations for the three and nine months ended December 31, 2018 and 2017 follow at the end of this release.

Conference Call

Aethlon will hold a conference call today, Monday, February 11, 2019 at 4:30 p.m. eastern time to review financial results and recent corporate developments. Following management's formal remarks, there will be a question and answer session.

To listen to the call by phone, interested parties within the U.S. should call 1-844-836-8741 and international callers should call 1-412-317-5442. All callers should ask for the Aethlon Medical, Inc. conference call.

A replay of the call will be available approximately one hour after the end of the call through February 18, 2019. The replay can be accessed via Aethlon Medical's website or by dialing 1-877-344-7529 (domestic) or 1-412-317-0088 (international) or Canada Toll Free at 1-855-669-9658. The replay conference ID number is 10128677.

About Aethlon Medical, Inc.

Aethlon Medical is focused on addressing unmet needs in global health.  The Aethlon Hemopurifier® is a clinical-stage immunotherapeutic device designed to combat cancer and life-threatening viral infections. In cancer, the Company believes that the Hemopurifier® depletes the presence of circulating tumor-derived exosomes that promote immune suppression, seed the spread of metastasis and inhibit the benefit of leading cancer therapies. The Hemopurifier® is an FDA designated "Breakthrough Device" related to the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease cancer. The Hemopurifier also holds a Breakthrough Device designation related to life-threatening viruses that are not addressed with approved therapies.

Additionally, Aethlon owns 80% of Exosome Sciences, Inc., which is focused on the discovery of exosomal biomarkers to diagnose and monitor cancer and neurological disease progression. Additional information can be found online at www.AethlonMedical.com and www.ExosomeSciences.com

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. Factors that may contribute to such differences include, without limitation, the Company's ability to raise additional funds and maintain its listing on the Nasdaq Capital Market, or any other national securities exchange, the risk that the Company or its subsidiary will not be able to commercialize its products, including the Hemopurifier, that the FDA will not approve the initiation or continuation of the Company's clinical programs or provide market clearance of the Company's products, the Company's ability to complete the development of the Hemopurifier and other planned products, the Company's ability to manufacture its products either internally or through outside companies, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. The foregoing list of risks and uncertainties is illustrative, but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended March 31, 2018, and in the Company's other filings with the Securities and Exchange Commission, including its quarterly Reports on Form 10-Q. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances.

Company Contact:

Jim Frakes, CFO
jfrakes@aethlonmedical.com
858-459-7800 extension 3300


AETHLON MEDICAL, INC. AND SUBSIDIARIES

Condensed Consolidated Balance Sheet







ASSETS




December 31, 2018


March 31, 2018







CURRENT ASSETS






Cash


$4,824,901


$6,974,070


Accounts receivable


-


74,813


Prepaid expenses


35,067


181,367







TOTAL CURRENT ASSETS


4,859,968


7,230,250








Property and equipment, net


9,669


27,552


Patents, net


68,959


75,832


Deposits


12,159


18,270







TOTAL NONCURRENT ASSETS


90,787


121,654








TOTAL ASSETS


$4,950,755


$7,351,904













LIABILITIES AND STOCKHOLDERS' EQUITY







CURRENT LIABILITIES






Accounts payable 


69,613


124,450


Due to related parties


69,750


90,366


Convertible notes payable, net


932,014


-


Other current liabilities


709,348


263,141







TOTAL CURRENT LIABILITIES


1,780,725


477,957







NONCURRENT LIABILITIES






Convertible notes payable, net


-


841,153

TOTAL NONCURRENT LIABILITIES


-


841,153







TOTAL LIABILITIES


1,780,725


1,319,110







COMMITMENTS AND CONTINGENCIES











EQUITY












Common stock, par value of $0.001, 30,000,000 shares authorized; 18,577,123 and 17,739,511 issued and outstanding


18,577


17,740


Additional-paid in capital


107,283,829


105,574,014


Accumulated deficit


(104,010,327)


(99,457,714)







TOTAL STOCKHOLDERS' EQUITY BEFORE NONCONTROLLING INTERESTS

3,292,079


6,134,040







Noncontrolling interests


(122,049)


(101,246)







TOTAL STOCKHOLDERS' EQUITY


3,170,030


6,032,794








TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY


$4,950,755


$7,351,904

 



AETHLON MEDICAL, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Operations

For the three and nine month periods ended December 31, 2018 and 2017





























Three Months


Three Months


Nine Months


Nine Months



Ended 12/31/18


Ended 12/31/17


Ended 12/31/18


Ended 12/31/17










Government contract revenue


$-


$74,813


$149,625


$74,813










OPERATING COSTS AND EXPENSES









Professional fees


587,192


439,117


1,449,218


1,165,318

Payroll and related


1,161,531


663,245


2,426,828


1,911,553

General and administrative


215,150


136,078


681,678


557,991



1,963,873


1,238,440


4,557,724


3,634,862










OPERATING LOSS


(1,963,873)


(1,163,627)


(4,408,099)


(3,560,049)










OTHER (INCOME) EXPENSE









Loss on debt extinguishment


-


-


-


376,909

Loss on share for warrant exchanges


-


-


-


130,214

Interest and other debt expenses


55,107


55,912


165,317


306,495



55,107


55,912


165,317


813,618










NET LOSS 


$(2,018,980)


$(1,219,539)


$(4,573,416)


$(4,373,667)










Loss attributable to noncontrolling interests


(5,940)


(4,532)


(20,803)


(12,972)










NET LOSS ATTRIBUTABLE TO AETHLON MEDICAL, INC.

$(2,013,040)


$(1,215,007)


$(4,552,613)


$(4,360,695)










Basic and diluted net loss available to common stockholders per share


$              (0.11)


$              (0.08)


$              (0.25)


$              (0.40)










Weighted average number of common shares outstanding


18,050,165


14,950,701


17,865,176


10,927,106

 

SOURCE Aethlon Medical, Inc.


These press releases may also interest you

at 16:09
Varian today announced its third quarter fiscal year 2019 earnings release date. The Company will report results for the third quarter of fiscal year 2019 after market close on Wednesday, July 24, 2019. The news release will be followed by a...

at 16:05
EACO Corporation today reported the results for its quarter ended May 31, 2019. Net sales, net income and earnings per share were as follows for the three months ended May 31, 2019 and 2018 (dollars in thousands, except per share information):...

at 16:05
Insulet Corporation (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, today announced plans to release its financial results for the second quarter of 2019 on August 5, 2019...

at 16:05
Altus Group Limited ("Altus Group" or "the Company") , a leading provider of software, data solutions and independent advisory services to the global commercial real estate industry, is hosting an investor update conference call and live webcast...

at 16:05
H.B. Fuller Company today reported financial results for the second quarter that ended on June 1, 2019. Items of Note for Second Quarter 2019: Net income was $37 million or $0.70 per diluted share (EPS), and adjusted...

at 16:05
Record net sales of $671 million, reflecting 9% growth over last year (8% organic growth) Operating margin expansion of 140 basis points Announces 6% increase in quarterly dividend payoutWebcast to be held Thursday, June 27, 2019, at 8:30 AM ET...



News published on 11 february 2019 at 16:15 and distributed by: